When was Excelra founded?

Excelra was founded in 2001 and raised its 1st funding round 15 years after it was founded.

Where is Excelra located?

Excelra is headquartered in Hyderabad, India. It is registered at Plot 28A IDA Nacharam, Hyderabad, Hyderabad, Telangana, India, 500076.

Which legal entities is Excelra associated with?

Excelra is associated with EXCELRA KNOWLEDGE SOLUTIONS PRIVATE LIMITED.

How many employees does Excelra have?

As of Sep 30, 2026, the latest employee count at Excelra is 1046.

Is Excelra a funded company?

Excelra is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jul 29, 2016.

When was the latest funding round of Excelra?

Excelra's latest funding was a $***** Seed round on Jul 29, 2016, with participation from 1 investor.

What is the annual revenue of Excelra?

Annual revenue of Excelra is between ₹50 Cr and ₹100 Cr as on Mar 31, 2020

Where does Excelra rank among its competitors?

Excelra ranks 209th amongst 1972 active competitors, of which 449 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of Excelra?

Excelra's top competitors include Antheia, Transcenta and Akeso. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

Excelra - 2026 Company Profile, Team, Funding, Competitors & Financials

Excelra is a seed company based in Hyderabad (India), founded in 2001 by Venkata Sanjayreddy Sanjayreddy Gunupati. It operates as a Developer of a bioinformatics platform for the in silico analysis of drug candidate. Excelra has raised $164K in funding from Destiny Investments. The company has 1972 active competitors, including 449 funded and 319 that have exited. Its top competitors include companies like Antheia, Transcenta and Akeso.

Company Details

Excelra develops a bioinformatics platform for the in silico analysis of drug candidate. The company's product GOSTAR is a SAR database that provides information on SAR, ADME, toxicity, preclinical, clinical, and structural data, GOBIOM is a repository of biomarkers reported in pre-clinical, clinical and exploratory phases, CTOD is a Clinical Trial Outcome Database. The company also develops and markets a suite of clinical trial outcomes databases. It also develops clinical databases that support MBMA on a custom basis. It also offers services for drug and biomarker discovery. It was previously known as GVK Informatics.

Website: excelra.com
Social
Email ID: *****@excelra.com
Phone Number: +91 **********
Registered Address: Plot 28A IDA Nacharam, Hyderabad, Hyderabad, Telangana, India, 500076

Key Metrics

Founded Year

2001

Location

Hyderabad, India

Stage

Seed

Total Funding

$164K in 1 round

Latest Funding Round

Seed, Jul 29, 2016, $*****

Investors

Destiny Investments & 5 more

Ranked

209^th among 1972 active competitors

Annual Revenue

₹50 - ₹100 Cr as on Mar 31, 2020

Employee Count

1,046 as on Sep 30, 2026

Investment & Acquisitions

BISC Global & 2 more

Similar Companies

Antheia & 2678 more

View Excelra's full profile

Excelra is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
EXCELRA KNOWLEDGE SOLUTIONS PRIVATE LIMITED CIN: U72200TG2014PTC093303 , India, Amalgamated	Mar 04, 2014	₹50 - ₹100 Cr (As on Mar 31, 2020)	574 (As on Mar 01, 2026)

Excelra has raised a total funding of $164K over 1 round. Its latest funding round was a Seed round on Jul 29, 2016 for $*****. 1 investor participated in its latest round. Excelra has 1 institutional investor and 5 angel investors.

Here is the list of recent funding rounds of Excelra:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 29, 2016	2582816	Seed	4878015	2391351	4775300	7018336

Access funding benchmarks and valuations. Sign up today!

View details of Excelra's funding rounds and investors

The founders of Excelra is Venkata Sanjayreddy Sanjayreddy Gunupati.

Here are the details of Excelra's key team members:

Venkata Sanjayreddy Sanjayreddy Gunupati: of Excelra. They are also an angel investor in 1 startup and serve on the board of 1 company.
Contact Info: 1 phone number

Excelra's Board of Directors

Excelra's board has 4 active members. Venkata Sanjayreddy Sanjayreddy Gunupati and Davinder Singh Brar are part of team and Sudip Nandy and Sidharth Reddy Indukuri are independent board members.

Here is the list of Excelra's board of directors:

Name	Type	Representing	Status	Duration
Venkata Sanjayreddy Sanjayreddy Gunupati	Team	-	Current	12y 6m
Davinder Singh Brar	Team	-	Current	12y 6m
Sudip Nandy	Independent board member	-	Current	4y 11m
qnvxhpz	Independent board member	-	Past	5y 2m

View details of Excelra's Founder profiles and Board Members

Excelra's employee count trend

Excelra has 1,046 employees as of Sep 26. Here is Excelra's employee count trend over the years:

Uncover Excelra's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Excelra include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of Excelra, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
5th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
6th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
7th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
8th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	62/100
9th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Maverick Ventures, SoftBank Vision Fund & 16 others	62/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
209th	Excelra 2001, Hyderabad (India), Seed	Developer of a bioinformatics platform for the in silico analysis of drug candidate	$164K	Destiny Investments & 5 others	43/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Excelra's competitors? Click here to see the top ones

Excelra has made 2 investments in Anlitiks and ProofPilot and acquired BISC Global.

Here is the list of these investments and acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Apr 19, 2023	Acquisition	BISC Global	2017	Ghent (Belgium)
Apr 19, 2022	Investments	Anlitiks	2017	Needham (United States)
Apr 04, 2022	Investments	ProofPilot	2012	New York City (United States)